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Thrombin is a serine protease that plays a crucial role in
hemostasis, ﬁbrinolysis, cell proliferation, and migration.
Thrombin binding aptamer (TBA) is able to inhibit the activity
of thrombin molecule via binding to its exosite I. This 15-nt
DNA oligonucleotide forms an intramolecular, antiparallel
G-quadruplex structure with a chair-like conformation. In this
paper, we report on our investigations on the inﬂuence of certain
modiﬁed nucleotide residues on thermodynamic stability,
folding topology, and biological properties of TBA variants. In
particular, the effect of single incorporation of a novel 4-thio-
uracil derivative of unlocked nucleic acid (UNA), as well as single
incorporation of 4-thiouridine and all four canonical UNAs, was
evaluated. The studies presented herein have shown that 4-thio-
uridine in RNA and UNA series, as well as all four canonical
UNAs, can efﬁciently modulate G-quadruplex thermodynamic
and biological stability, and that the effect is strongly position
dependent. Interestingly, TBA variants containing the modiﬁed
nucleotide residues are characterized by unchanged folding
topology. Thrombin time assay revealed that incorporation of
certain UNA residues may improve G-quadruplex anticoagulant
properties. Noteworthy, some TBA variants, characterized by
decreased ability to inhibit thrombin activity, possess signiﬁcant
antiproliferative properties reducing the viability of the HeLa
cell line even by 95% at 10 mM concentration.
INTRODUCTION
In recent years there has been growing interest in discovery and
application of therapeutic oligonucleotides. They constitute a wide
group of compounds consisting of single- or double-stranded DNA
or RNA constructs. According to structure and mechanism of action,
therapeutic oligonucleotides could be divided into a few classes
including antisense oligonucleotides, small interfering RNAs, ribo-
zymes, DNAzymes, decoys, CpG oligonucleotides, and aptamers.1
Aptamers are short, single-stranded oligonucleotides whose
sequences determine their folding into secondary structure.2,3
Accordingly, they are able to bind with high afﬁnity and selectivity
to various targets including proteins,4,5 peptides,5 small chemical
compounds,4,6 and metal ions,7 and thereby to initiate a biological
response. Due to those interesting properties they are termed chem-
ical antibodies. The main method to evolve a new aptamer is in vitro
selection via a process termed systematic evolution of ligands by
exponential enrichment (SELEX).3,8
One of the ﬁrst aptamers discovered was thrombin binding aptamer
(TBA), selected by Louis Bock in 1992.9 It is a 15-nt DNA oligonucle-
otide, which forms an intramolecular, antiparallel G-quadruplex
structure with a chair-like conformation (Figure 1A).10 The core of
TBA consists of the two G-tetrads, each built up with four guanosine
residues stabilized by Hoogsteen hydrogen bonds11,12 and displaying
syn or anti conformation of the glycosidic bonds.13,14 G-tetrads
within TBA are linked by three loops: two TT edge-wise loops and
one TGT loop.15,16 Structural studies indicate that T4 and T13 residues
stabilize G-quadruplex structure due to stacking on the neighboring
G-quartet and formation of T-T base pair via carbonyl and imino pro-
ton of each base. On the contrary, T3, T7, and T12 residues are not
involved in intramolecular interactions and are pointed outside the
G-quadruplex core. Based on crystallographic and nuclear magnetic
resonance (NMR) studies it was determined that TBA interacts
with thrombin anion exosite I via two TT loops.16–18 Comprehensive
structural studies showed that T3 and T12 nucleobases form a pincer-
like motif that grips the ﬁbrinogen recognition site region.
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The superior anticoagulant properties of TBA were noticed simulta-
neously with its discovery. However, the therapeutic dose was too
high to successfully accomplish clinical trials.19 Fortunately, the
promising properties of TBA such as reversibility of action, small
size, and simplicity of chemical synthesis prompted scientists to
make attempts to create new TBA variants that would provide signif-
icant therapeutic beneﬁt, outweighing the side effects.12 Thus far, a
wide variety of modiﬁcations were tested for the ability to improve
anticoagulant properties of TBA, including 4-thio-20-deoxyuridine,20
LNAs (locked nucleic acids),21 UNAs (unlocked nucleic acids),22,23
20-deoxy-isoguanosine,24 RNA25 and 20-O-methyl-RNA nucleo-
tides,25 methylphosphonate25 and phosphorothioate internucleoside
linkages,25,26 partial inversion of TBA polarity with a 50-5027,28 and
a 3ʹ-3ʹ internucleoside linkage,29 and changes of the loop size and
sequence.30 Three of these modiﬁcations, i.e., 4-thio-20-deoxyuridine,
20-deoxy-isoguanosine, and unlocked nucleic acids, were found as
favorable for TBA anticoagulant properties. In addition, the latest
literature has demonstrated the possibility of changing the
anticoagulant activity of TBA for antiproliferative activity via intro-
duction of a dibenzyl linker.31
Herein, a novel 4-thiouracil derivative of UNA (UNA-s4U) has been
synthesized for the ﬁrst time and introduced into TBA. We have
examined the inﬂuence of single and multiple introductions of
UNA-s4U, as well as of regular UNA-A, UNA-C, UNA-G, UNA-U,
and 4-thiouridine (RNA-s4U) on TBA folding topology (Figure 1).
Furthermore, the potential changes in G-quadruplex thermodynamic
stability induced by the modiﬁed nucleoside residues were investi-
gated. Finally, we have analyzed the anticoagulant and antiprolifera-
tive potential of the novel, chemically modiﬁed, TBA variants.
RESULTS AND DISCUSSION
It has been demonstrated that the replacement of T or dG within the
TGT loop by other 20-deoxynucleosides does not perturbG-quadruplex
structure and can be favorable for thermodynamic stability of the TBA
molecule.30 Moreover, previously published data concerning UNA-
modiﬁed TBA variants described the consequences of substitution of
dG by UNA-G and T by UNA-U.22 Herein we have extended
these studies by the introduction of other types of UNA residues,
i.e., UNA-A, UNA-C, or UNA-G instead of T and UNA-A, UNA-C,
or UNA-U instead of dG. According to already published data, the
thermodynamically and biologically most unfavorable positions for
the introduction of UNA residues into TBA was any position of the
G-quartet. Therefore, in this paper, UNA residues were introduced
only at the positions of TBA loops: T3, T4, T7, G8, T9, T12, or T13.
It was reported that TBA containing four 4-thio-20-deoxyuridine nu-
cleotides at positions T3, T7, T9, and T13 possess improved anticoag-
ulant activity.20 Increased biological activity was also described for
TBA modiﬁed by UNA-U at position T7.22 Based on these ﬁndings,
we designed TBA variants with single substitution of a novel UNA de-
rivative, i.e., UNA-4-thiouracil, thus combining both structural com-
ponents reported to be favorable for biological activity.18,20 Novel
TBA variants containing a single substitution of UNA-4-thiouracil
or 4-thiouridine at all possible positions of the loops were synthesized
and studied, and we also analyzed the TBA variants with four UNA-4-
thiouracil or 4-thiouridine residues at positions T3, T7, T9, and T12 or
T3, T7, T9, and T13.
CD Spectroscopy
Circular dichroism (CD) spectroscopy is a technique that allows
determination of probe conformation based on the differences in
absorbance of right- or left-handed circularly polarized light.32
Nucleotide residues are optically active elements that generate CD
signal. Different spatial orientation of the heterocyclic bases in certain
nucleic acid secondary structures results in occurrence of character-
istic CD spectra providing information about speciﬁc structural geom-
etry or folding topology. G-quadruplexes may possess one of two
folding topologies: parallel or antiparallel.33 The parallel folding topol-
ogy occurs when all strands display the same orientation and is char-
acterized by the presence of one positive CD band around 260 nm and
one negative near 240 nm. When the antiparallel folding topology is
observed, CD spectra are characterized by the presence of one positive
band around 290 nm and one negative band near 260 nm.
The CD spectra obtained for TBA variants containing single or multi-
ple substitution of RNA-s4U, UNA-s4U, UNA-A, UNA-C, UNA-G,
andUNA-Udisplay the typical proﬁle for an antiparallelG-quadruplex
Figure 1. Schematic Representation of TBA and Modified Residues Applied in the Studies
Structure of (A) thrombin binding aptamer (TBA), (B) novel 4-thiouracil derivative of UNA, (C) UNA nucleotide monomer, and (D) 4-thiouridine.
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structure.Twopositive bands around245 and295nmandonenegative
band near 265 nmwere observed for all TBA variants (Figure 2A).10,34
Based on this result, it can be concluded that introduction of modiﬁed
nucleotides into TBA at the studied positions has no inﬂuence on the
overall G-quadruplex folding topology, and all analyzed TBA variants
formantiparallelG-quadruplex structure at physiological temperature.
Thermal Difference Spectra
Thermal difference spectroscopy (TDS) constitutes a complementary
technique to CD spectroscopy and enables evaluation of oligonucle-
otides structure in solution.35 Speciﬁc nucleic acids structures possess
characteristic TDS patterns reﬂecting subtle alterations in stacking
interactions.
The TDS obtained for TBA variants containing single or multiple
substitution of RNA-s4U, UNA-s4U, UNA-A, UNA-C, UNA-G,
and UNA-U is characterized by a similar pattern with two positive
bands around 240 and 270 nm and two negative bands near 260
and 295 nm (Figure 2B). According to previously published data
and to the TDS of unmodiﬁed TBA, the proﬁle of the spectra is char-
acteristic for an antiparallel G-quadruplex structure.22 Taking under
consideration the above data, it can be concluded that the introduc-
tion of modiﬁed nucleotides, i.e., canonical UNAs, UNA-s4U, and
RNA-s4U, into TBA has no inﬂuence on the overall G-quadruplex
folding topology. The results are consistent with those derived from
the CD spectra and thermodynamic studies.
Thermal Denaturation Measurements
Thermodynamic Analysis of TBA Variants Modified with UNA-A,
UNA-C, UNA-G, or UNA-U
Thermodynamic analysis revealed that the most energetically
favorable is replacement of thymidine at position T7 by UNA-A,
UNA-C, or UNA-G (Table 1). The presence of UNA-A, UNA-C,
and UNA-G at this position induced change of Gibbs free energy
by 0.37, 0.59, and 0.53 kcal/mol, respectively. Previously pub-
lished data indicate that the presence of UNA-U at position T7 caused
stabilization by 0.50 kcal/mol.22 Our results are strictly comparable
with the inﬂuence of UNA-U. It suggests that stabilization of TBA
structure by UNAs at position T7 is rather due to increased ﬂexibility
of ribose moiety or the presence of additional 20OH group, and that
the type of heterocyclic base at this position is not crucial for structure
stabilization. Analysis of the published NMR and X-ray structures of
unmodiﬁed TBA supports this observation, because thymidine resi-
due at position T7 is ﬂipped out toward solution.36–38 If the residue
does not interact with the rest of the G-quadruplex structure, the
high tolerance as observed at this position toward changes of the het-
erocyclic part of the residue, i.e., different size of aromatic surface and
various exocyclic groups, is not surprising.
On the contrary, signiﬁcant dependence betweenTBA thermodynamic
stability and the type of heterocyclic base is observed at position T9
(Table 1). The presence of UNA-G caused increase of thermodynamic
stability by 0.29 kcal/mol (DDG37 = 0.29 kcal/mol), whereas
introduction of UNA-A or UNA-C induced destabilization by 0.53
and 1.30 kcal/mol (DDG37 = +0.53 and +1.30 kcal/mol), respectively.
Similarly, also UNA-U at position T9 decreased G-quadruplex thermo-
dynamic stability (increased DG37) by 1.08 kcal/mol.
22 These data
indicate that UNApyrimidines placed at position T9 aremore unfavor-
able for G-quadruplex formation than UNA purines. According
to TBA structure, thymidine residue at position T9 stack over the G-
quartet, and apparently the presence of different heterocyclic bases
at this position may interrupt this type of interaction.36,37 Additionally,
a more ﬂexible ribose moiety might hinder optimal orientation for the
interfaces between the G-tetrad and the aromatic surfaces of the nucle-
obase. Nevertheless, the increase of TBA thermodynamic stability by
UNA-G at position T9 might be due to some additional, favorable
interactions between the guanine moiety and the G-quartet.
The highest destabilization was observed for TBA variants modiﬁed
with UNAs at position G8 (Table 1). The replacement of dG at
this position by UNA-A, UNA-C, or UNA-U induced a decrease
Figure 2. Spectral Analysis of G-quadruplex Folding Topology
Representative circular dichroism spectra (A) and thermal difference spectra (B) of
unmodified TBA (black lines) and TBA variants modified with canonical UNA (green
lines), UNA-s4U (blue lines), and RNA-s4U (red lines).
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in thermodynamic stability of the resulting G-quadruplexes by 1.74,
2.03, and 1.76 kcal/mol, respectively. The effects are deﬁnitely more
unfavorable relative to introduction of UNA-G at position G8
(DDG37 = 1.08 kcal/mol).
22 The guanosine residue at position G8
forms hydrogen bonds with the G-tetrad within TBA.39 Therefore,
optimal orientation of the residue to interact with the G-quartet is
likely hindered by the increased ﬂexibility of UNA, and as a conse-
quence destabilization is observed. Moreover, higher destabilization
induced by UNA-A, UNA-C, or UNA-U in reference to UNA-G is
probably due to the lack or spatial shift of exocyclic groups
that would be able to form stable, effective hydrogen bonds with
the G-tetrad.
Introduction of UNA-A or UNA-C at position T4 and UNA-A,
UNA-C, or UNA-G at position T13 decreased the thermodynamic
stability of TBA by approximately 1.5 kcal/mol (Table 1). Both thymi-
dine residues in unmodiﬁed TBA are involved in favorable hydrogen
bonding and stacking interactions with the G-quadruplex core, and
thus increase of sugar ﬂexibility and change to other types of nucleo-
base cause clear destabilization.18,40 The results stay in accordance
with previously published data regarding the substitution of thymi-
dine by UNA-U, which destabilized the TBA structure by 0.8 and
1.4 kcal/mol at positions T4 and T13, respectively.22
Minor destabilization of the G-quadruplex structure was observed
whenUNAswere placed at position T3 or T12 (Table 1). AUNA-A res-
idue decreased the thermodynamic stability by 0.31–0.37 kcal/mol,
whereas UNA-C and UNA-G caused only negligible destabilization
up to 0.10 kcal/mol. High tolerance to chemical modiﬁcation of those
two positions is probably due to the lack of interactions between T3
and T12 residues with the rest of the TBA molecule.
Thermodynamic Analysis of TBA Variants Modified with UNA-
4-Thiouracil and 4-Thiouridine
Thermodynamic analysis showed that the most energetically
favorable was introduction of 4-thiouridine at position T12
(DDG37 = 0.53 kcal/mol; Table 2). On the contrary, the presence
of UNA-4-thiouracil at the same position did not inﬂuence the
thermodynamic stability of TBA. Similarly, also the substitution of
thymidine by UNA-4-thiouracil at position T3 was neutral for ther-
modynamic stability of TBA, but the presence of the RNA counter-
part caused stabilization by 0.31 kcal/mol in reference to unmodiﬁed
TBA. Previously reported data demonstrated that the presence of
UNA-U at position T3 or T12 increased the thermodynamic stability
of TBA by 0.23 and 0.15 kcal/mol, respectively.22 Less favorable
inﬂuence of UNA-s4U in reference to UNA-U is therefore presum-
ably due to the presence of the chemically modiﬁed nucleobase.
Table 1. Thermodynamic Parameters of G-Quadruplex Formation of TBA Variants Modified with UNA-A (AU), UNA-C (CU), UNA-G (GU), and UNA-U (UU)
Position of Modiﬁcation Sequence (5ʹ-3ʹ)
Average of Curve Fits
DH (kcal/mol) DS (eu) DG37 (kcal/mol) TM (C) DDG37 (kcal/mol) DTM (C)
GGTTGGTGTGGTTGG 41.2 ± 0.9 127.2 ± 2.7 1.74 ± 0.02 50.7 0 0
T3 GGAUTGGTGTGGTTGG 39.5 ± 0.8 122.7 ± 2.4 1.43 ± 0.04 48.7 0.31 2.0
T3 GGCUTGGTGTGGTTGG 40.3 ± 0.4 124.3 ± 1.1 1.74 ± 0.01 51.0 0 0.3
T3 GGGUTGGTGTGGTTGG 40.5 ± 0.9 125.1 ± 2.9 1.66 ± 0.05 50.2 0.08 0.5
T4 GGTAUGGTGTGGTTGG 33.5 ± 0.3 107.4 ± 0.9 0.21 ± 0.02 39.0 1.53 11.7
T4 GGTCUGGTGTGGTTGG 34.7 ± 1.0 110.9 ± 3.2 0.29 ± 0.04 39.6 1.45 11.1
T7 GGTTGGAUGTGGTTGG 43.6 ± 1.0 133.9 ± 3.1 2.11 ± 0.05 52.8 0.37 2.1
T7 GGTTGGCUGTGGTTGG 44.4 ± 1.4 135.7 ± 4.3 2.33 ± 0.06 54.2 0.59 3.5
T7 GGTTGGGUGTGGTTGG 44.1 ± 1.2 134.8 ± 3.6 2.27 ± 0.10 53.9 0.53 3.2
G8 GGTTGGTAUTGGTTGG 34.9 ± 1.8 112.7 ± 5.7 0.00 ± 0.01 37.0 1.74 13.7
G8 GGTTGGTCUTGGTTGG 35.2 ± 1.3 114.4 ± 4.2 0.29 ± 0.03 34.5 2.03 16.2
G8 GGTTGGTUUTGGTTGG 36.3 ± 0.5 117.0 ± 1.6 0.02 ± 0.02 36.8 1.76 13.9
T9 GGTTGGTGAUGGTTGG 43.4 ± 1.1 136.1 ± 3.4 1.21 ± 0.05 45.9 0.53 4.8
T9 GGTTGGTGCUGGTTGG 40.6 ± 2.8 129.5 ± 9.0 0.44 ± 0.07 40.4 1.30 10.3
T9 GGTTGGTGGUGGTTGG 47.3 ± 1.7 146.1 ± 5.1 2.03 ± 0.15 50.9 0.29 0.2
T12 GGTTGGTGTGGAUTGG 37.8 ± 0.7 117.3 ± 2.2 1.37 ± 0.02 48.7 0.37 2.0
T12 GGTTGGTGTGGCUTGG 39.6 ± 0.6 122.3 ± 1.8 1.63 ± 0.03 50.3 0.11 0.4
T12 GGTTGGTGTGGGUTGG 39.9 ± 1.3 123.3 ± 4.0 1.64 ± 0.08 50.3 0.1 0.4
T13 GGTTGGTGTGGTAUGG 34.8 ± 0.2 111.7 ± 0.7 0.19 ± 0.02 38.7 1.55 12.0
T13 GGTTGGTGTGGTCUGG 34.3 ± 1.0 109.9 ± 3.0 0.16 ± 0.03 38.4 1.58 12.3
T13 GGTTGGTGTGGTGUGG 35.3 ± 0.7 113.4 ± 2.1 0.16 ± 0.05 38.4 1.58 12.3
Buffer: 100 mM KCl, 20 mM sodium cacodylate, 0.5 mM EDTA(Na)2 (pH 7.0).
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The presence of 4-thiouridine at position T7 increases the thermody-
namic stability of TBA by 0.48 kcal/mol, whereas UNA-4-thiouracil
stabilizes by 0.34 kcal/mol (Table 2). The only minor difference
observed for the two modiﬁcations at position T7 suggests that the
ﬂexibility of the ribose moiety at this position is not governing the
thermodynamic stability. Again, this is probably due to the structural
orientation of nucleobase at position T7, which is headed toward the
solution without interacting with the rest of the G-quadruplex mole-
cule.38 Interestingly, 4-thiouridine introduced at position T9 likewise
stabilizes TBA (DDG37 =0.42), but the effect of UNA-4-thiouracil
at position T9 is opposite and substantial destabilization is observed
(DDG37 = 0.95 kcal/mol). The difference of DDG37 between
UNA-s4U and RNA-s4U placed at position T9 might be because
of increased ﬂexibility of UNA, which hinders optimal orientation
of the nucleobase for stacking interactions with the G-tetrad. A
similar effect was observed previously for UNA-U at position T9
(DDG37 = 1.08 kcal/mol).
22
Introduction of 4-thiouridine or UNA-4-thiouracil at position T4 or
T13 decreased the thermodynamic stability of TBA. The presence of
the above modiﬁcations caused destabilization by 1.00 and
0.94 kcal/mol for RNA-s4U and UNA-s4U at position T4, and 1.18
and 1.08 kcal/mol for RNA-s4U and UNA-s4U at position T13,
respectively (Table 2). Comparable thermodynamic effects observed
for UNA-s4U and RNA-s4U at the above positions suggest that the
change of the thermodynamic stability of TBA strongly depends on
the type of nucleobase (less electronegative sulfur atom in reference
to oxygen), not the type of sugar moiety. The observed decrease of
thermodynamic stability is probably due to the disturbance of stack-
ing and/or hydrogen bonding between the nucleobase at position T4
or T13 and the remaining part of the G-quadruplex.
The most unfavorable change of the thermodynamic stability of TBA
was induced by the presence of UNA-4-thiouracil at position G8
(DDG37 = 1.70 kcal/mol; Table 2). Previously discussed data showed
that UNA-U at the same position caused similar destabilization
(DDG37 = 1.76 kcal/mol). This suggests that decrease of TBA ther-
modynamic stability observed for UNA-modiﬁed variants at position
G8 is rather an effect of substitution of purine by pyrimidine moiety
and that further modiﬁcation of base (O/S) does not contribute
additionally to the destabilization. On the contrary, the presence of
4-thiouridine at position G8 decreases thermodynamic stability of
TBA by only 0.47 kcal/mol. Thus, we can conclude that not only sub-
stitution of purine by pyrimidine, but also sugar ﬂexibility at position
G8 is pivotal for the thermodynamic stability of TBA.
As expected, the thermodynamic effects observed for single modiﬁca-
tions within TBA were additive, i.e., the theoretical DG37 values
of multi-modiﬁed TBA variants were approximately the sum of
the experimental DG37 value of unmodiﬁed TBA and the
Table 2. Thermodynamic Parameters of G-Quadruplex Formation of TBA Variants Modified with RNA-s4U (s4UR) and UNA-s4U (s4UU)
Position of Modiﬁcation Sequence (5ʹ-3ʹ)
Average of Curve Fits
DH (kcal/mol) DS (eu) DG37 (kcal/mol) TM (C) DDG37 (kcal/mol) DTM (C)
GGTTGGTGTGGTTGG 41.2 ± 0.9 127.2 ± 2.7 1.74 ± 0.02 50.7 0 0
T3 GGs4URTGGTGTGGTTGG 41.7 ± 2.6 127.8 ± 7.8 2.05 ± 0.16 52.7 0.31 2.0
T3 GGs4UUTGGTGTGGTTGG 40.3 ± 1.1 124.3 ± 3.5 1.74 ± 0.04 51.0 0 0.3
T4 GGTs4URGGTGTGGTTGG 40.4 ± 3.3 127.8 ± 7.5 0.74 ± 0.05 42.8 1.00 7.9
T4 GGTs4UUGGTGTGGTTGG 45.6 ± 8.6 144.4 ± 27.7 0.80 ± 0.10 42.5 0.94 8.2
T7 GGTTGGs4URGTGGTTGG 44.0 ± 1.1 134.8 ± 3.4 2.22 ± 0.05 53.5 0.48 2.8
T7 GGTTGGs4UUGTGGTTGG 40.2 ± 0.6 122.8 ± 1.9 2.08 ± 0.03 53.9 0.34 3.2
G8 GGTTGGTs4URTGGTTGG 39.6 ± 2.3 123.5 ± 7.1 1.27 ± 0.07 47.3 0.47 3.4
G8 GGTTGGTs4UUTGGTTGG 37.3 ± 0.7 120.2 ± 2.1 0.04 ± 0.02 37.3 1.70 13.4
T9 GGTTGGTGs4URGGTTGG 43.2 ± 3.2 132.5 ± 10.0 2.16 ± 0.09 53.3 0.42 2.6
T9 GGTTGGTGs4UUGGTTGG 41.6 ± 2.9 131.6 ± 9.1 0.79 ± 0.08 43.0 0.95 7.7
T12 GGTTGGTGTGGs4URTGG 44.2 ± 1.3 135.1 ± 4.2 2.27 ± 0.05 53.8 0.53 3.1
T12 GGTTGGTGTGGs4UUTGG 40.6 ± 0.6 125.2 ± 2.0 1.74 ± 0.03 50.9 0 0.2
T13 GGTTGGTGTGGTs4URGG 35.9 ± 0.8 114.0 ± 2.7 0.56 ± 0.04 41.9 1.18 9.5
T13 GGTTGGTGTGGTs4UUGG 37.3 ± 1.1 118.2 ± 3.5 0.66 ± 0.02 42.6 1.08 8.1
T3, T7, T9, T12 GGs4URTGGs4URGs4URGGs4URTGG 46.6 ± 1.2 139.5 ± 3.5 3.30 ± 0.08 60.6 1.56 9.9
T3, T7, T9, T12 GGs4UUTGGs4UUGs4UUGGs4UUTGG 37.8 ± 2.8 118.0 ± 8.9 1.23 ± 0.08 47.4 0.51 3.3
T3, T7, T9, T13 GGs4URTGGs4URGs4URGGTs4URGG 37.9 ± 1.1 117.6 ± 3.4 1.39 ± 0.05 48.8 0.35 1.9
T3, T7, T9, T13 GGs4UUTGGs4UUGs4UUGGTs4UUGG 26.2 ± 3.6 84.0 ± 11.5 0.16 ± 0.08 38.9 1.58 11.8
Buffer: 100 mM KCl, 20 mM sodium cacodylate, 0.5 mM EDTA(Na)2 (pH 7.0).
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thermodynamic effects (DDG37) caused by single modiﬁcation at
particular positions. The additivity for the majority of studied TBA
variants was in the range of 83% to 94% (data not shown). Simulta-
neous introduction of four 4-thiouridines at positions T3, T7, T9,
and T12 into TBA caused an increase of TBA thermodynamic stability
by 1.56 kcal/mol (Table 2). On the contrary, the presence of UNA
counterparts at the same positions caused destabilization of the G-
quadruplex structure by 0.51 kcal/mol. The presence of 4-thiouridine
or UNA-4-thiouracil at positions T3, T7, T9, and T13 always caused
destabilization (DDG37 = 0.35 and 1.58 kcal/mol for RNA-s4U and
UNA-s4U, respectively).
In general, the thermodynamic analysis discussed above showed
that the presence of 4-thiouridine is usually more favorable for ther-
modynamic stability of TBA than UNA-4-thiouracil. Nevertheless,
the majority of modiﬁed TBA variants described in this paper
possess negative DG37 value, indicating that at physiological
temperature (37C) the predominant species would be a folded
G-quadruplex structure. Accordingly, analysis of Tm (melting
temperature) versus concentration independence indicates that the
modiﬁed TBA variants form intramolecular G-quadruplexes.
Surprisingly, one TBA molecule modiﬁed with UNA-G at position
T4 showed intermolecular G-quadruplex folding (Supplemental
Information; Table S1). Nevertheless, at this moment it is difﬁcult
to explain the exact nature and origin of folding molecularity
change of this particular TBA variant.
Thrombin Time Assay
The inﬂuence of single or multiple introduction into TBA of
4-thiouridine in RNA and UNA series or canonical UNAs on the
anticoagulant properties was evaluated by the thrombin time assay.
It is a standard method that allows determination of the time needed
to form ﬁbrin clot after addition of exogenous thrombin to blood
plasma. The anticoagulant effect (AE) used herein to compare the
anticoagulant properties of TBA variants was calculated by subtrac-
tion of the clotting time for plasma with exogenous thrombin and
oligonucleotides from the clotting time for plasma with exogenous
thrombin only.
It was previously reported that the presence of a single UNA residue
at certain positions of TBA has a beneﬁcial inﬂuence on its anticoag-
ulant properties.22,23 The data obtained herein revealed that the
introduction of UNA residues has a different inﬂuence on the antico-
agulant activity of TBA depending on their exact positioning.
Modiﬁcation of position T7 was the most beneﬁcial for maintaining
TBA anticoagulant activity. TBA variant modiﬁed with UNA-C at
T7 possesses the most favorable, comparable with TBA, anticoagulant
properties (AE = 16.3 s; Table 3). On the contrary, the introduction of
UNA-A or UNA-G at this position causes a decrease of anticoagulant
activity (AE was 15.3 and 10.2 s, respectively; Table 3). According to
recent literature, the thymidine residue at T7 position is not involved
in thrombin binding or aptamer stabilizing interactions, reﬂecting
the high tolerance at this position toward substitution with
Table 3. The Anticoagulant Properties of TBA and TBA Variants Modified with Canonical UNAs (AU, CU, GU, UU), UNA-s4U (s4UU), and RNA-s4U (s4UR)
Position of Modiﬁcation Sequence (5ʹ-3ʹ) AE (s) Position of Modiﬁcation Sequence (5ʹ-3ʹ) AE (s)
GGTTGGTGTGGTTGG 17.3 T13 GGTTGGTGTGGTCUGG 0.6
T3 GGAUTGGTGTGGTTGG 8.0 T13 GGTTGGTGTGGTGUGG 0.5
T3 GGCUTGGTGTGGTTGG 4.7 T3 GGs4URTGGTGTGGTTGG 4.0
T3 GGGUTGGTGTGGTTGG 6.0 T3 GGs4UUTGGTGTGGTTGG 8.7
T4 GGTAUGGTGTGGTTGG 0.0 T4 GGTs4URGGTGTGGTTGG 1.0
T4 GGTCUGGTGTGGTTGG 0.1 T4 GGTs4UUGGTGTGGTTGG 0.4
T4 GGTGUGGTGTGGTTGG 0.2 T7 GGTTGGs4URGTGGTTGG 4.8
T7 GGTTGGAUGTGGTTGG 15.3 T7 GGTTGGs4UUGTGGTTGG 15.5
T7 GGTTGGCUGTGGTTGG 16.3 G8 GGTTGGTs4URTGGTTGG 5.7
T7 GGTTGGGUGTGGTTGG 10.2 G8 GGTTGGTs4UUTGGTTGG 3.7
G8 GGTTGGTAUTGGTTGG 4.2 T9 GGTTGGTGs4URGGTTGG 1.3
G8 GGTTGGTCUTGGTTGG 3.2 T9 GGTTGGTGs4UUGGTTGG 6.9
G8 GGTTGGTUUTGGTTGG 4.6 T12 GGTTGGTGTGGs4URTGG 5.0
T9 GGTTGGTGAUGGTTGG 5.5 T12 GGTTGGTGTGGs4UUTGG 8.3
T9 GGTTGGTGCUGGTTGG 6.9 T13 GGTTGGTGTGGTs4URGG 2.4
T9 GGTTGGTGGUGGTTGG 5.5 T13 GGTTGGTGTGGTs4UUGG 0.1
T12 GGTTGGTGTGGAUTGG 6.9 T3, T7, T9, T12 GGs4URTGGs4URGs4URGGs4URTGG 0.8
T12 GGTTGGTGTGGCUTGG 5.1 T3, T7, T9, T12 GGs4UUTGGs4UUGs4UUGGs4UUTGG 0.5
T12 GGTTGGTGTGGGUTGG 6.3 T3, T7, T9, T13 GGs4URTGGs4URGs4URGGTs4URGG 0.3
T13 GGTTGGTGTGGTAUGG 0.2 T3, T7, T9, T13 GGs4UUTGGs4UUGs4UUGGTs4UUGG 0.6
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UNA residues.38 Introduction of UNA into the aptamer loops caused
distinct decrease in TBA anticoagulant properties. Thus, the TBA
variants modiﬁed with UNA residues at positions T3, G8, T9, or T12
display signiﬁcantly reduced ability to inhibit thrombin activity
(the AE was in the range between 3.2 and 8.0 s; Table 3). The lowest
value of anticoagulant effect was observed for the TBA variant modi-
ﬁed with UNA-A, UNA-C, or UNA-G residue at position T4 or T13
(the AE was in range 0.1 to 0.5 s; Table 3). This can be explained
by the thrombin-TBA interaction model that assumes that the two
TT loops act as a pincer-like system that embraces the protruding
region of thrombin exosite I.18 In this mode of action, T4 and T13
nucleotides play the crucial role in hydrogen bonds formation with
thrombin amino acid residues. What is more, the T4 and T13 residues
contribute to the TBA stability by p-stacking interactions with the
guanine tetrads. Thus, the increase in ﬂexibility of this TBA fragment
via introduction of UNA residues results in disruption of intramolec-
ular and intermolecular interactions. The results obtained are consis-
tent with previously published data showing that the introduction of
UNA-U at positions T4 or T13 signiﬁcantly decreases the anticoagu-
lant properties of TBA.22
In the past decade 4-thio-20-deoxyuridine has received much atten-
tion because of its capability of improving oligonucleotide binding
afﬁnity to target protein,41,42 and a beneﬁcial inﬂuence of 4-thio-20-
deoxyuridine on TBA anticoagulant properties has been reported.20
In light of the above we decided to evaluate the inﬂuence of single
or multiple introduction of 4-thiouridine and UNA-4-thiouracil on
TBA anticoagulant properties. The TBA variant modiﬁed with
UNA-s4U residue at position T7 displays the most favorable antico-
agulant effect (the AE was 15.5 s; Table 3), almost being comparable
with TBA. The introduction of UNA-s4U and RNA-s4U residues at
other TBA positions reduced its ability to inhibit thrombin activity.
Further analysis revealed that the anticoagulant effect caused by single
substitution of UNA-s4U is more favorable than that induced by
RNA-s4U. The effects for both groups of modiﬁcations were in the
range between 6.9–15.5 s (UNA-s4U; Table 3) and 1.3–5.0 s (RNA-
s4U; Table 3). The observed differences can be a result of increased
ﬂexibility of loop fragments caused by the presence of the UNA moi-
eties. Interestingly, the above trend was opposite when RNA-s4U or
UNA-s4U residues were introduced at positions T4, G8, or T13. The
T4 and T13 residues are involved in the interactions with the thrombin
molecule,18 and their proper arrangement to interact with the protein
active site is therefore crucial. Presumably, the introduction of
UNA-s4U at positions T4 or T13 causes local, unfavorable structure
relaxation, which is manifested in the decrease of TBA anticoagulant
properties. TBA variants possessing multiple substitution of
RNA-s4U or UNA-s4U at positions T3, T7, T9, and T12 or T13 were
characterized by having in general lowest AE values (Table 3).
The data analysis of thrombin time assay conducted with different
solutions of selected TBA variants (0.0825, 0.165, 0.330, 0.495,
0.660, 0.825, and 1 mM) revealed that the observed anticoagulant
effect is strictly dependent on the concentration of oligomers. It
was possible to improve inhibitory properties of TBA variants
modiﬁed with UNA-A and UNA-C at position T7 via increasing
their concentration (Figure 3; Supplemental Information; Tables S2
and S3). The thrombin time values achieved for those oligomers
were 1.5-fold higher than for unmodiﬁed TBA (AE = 279.7 s for
UNA-A and UNA-C at T7, and 175.5 s for unmodiﬁed TBA).
Improvement of TBA anticoagulant properties was also observed
when UNA-s4U and UNA-G were introduced at the position T7.
However, in this case, the AE value was always below the AE value
determined for TBA. The remaining TBA variants were characterized
only by a slight improvement of anticoagulant properties provoked by
the increase of oligonucleotide concentration.
The results indicate a particularly favorable inﬂuence of introducing
nucleotide modiﬁcation at position T7 on TBA anticoagulant proper-
ties. Furthermore, the observed anticoagulant effect of the analyzed
aptamers is dependent on their concentration. It is possible to in-
crease the inhibitory potential of these oligonucleotides by raising
its concentration during injection to the plasma. All analyzed variants
possess anticoagulant properties, but only two of them are character-
ized by improved AE value in reference to the unmodiﬁed TBA.
Amidolytic Assay
Three main functional domains can be distinguished in the thrombin
structure: exosite I, exosite II, and active site.43–45 The exosite I has
been indicated as playing a key role for binding to ﬁbrinogen, prote-
ase-activated receptors,44 and activity modulators such as TBA.20 In
order to verify whether the introduction of modiﬁed nucleotides
into TBA has an inﬂuence on aptamer binding to this region, the
amidolytic assay was applied. It is a simple method to determine
the availability of the thrombin catalytic center by the addition of
the chromogenic substrate H-D-Phe-Pip-Arg-pNA and analysis
of the spectrophotometric change in the sample color intensity.
H-D-Phe-Pip-Arg-pNA is a short peptide, able to bind to the
Figure 3. Concentration Dependence of Anticoagulant Effect of Unmodified
TBA and TBA Variants
Analyzed TBA variants possessed: UNA-s4U at T3 (red triangles), UNA-s4U at T7
(red squares), UNA-s4U at T9 (red circles), UNA-A at T7 (orange squares), UNA-C at
T7 (gray squares), UNA-G at T7 (green squares), UNA-C at T9 (gray circles), UNA-A
at T3 (orange triangles), and UNA-A at T12 (orange stars).
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thrombin active site even though other functional domains are occu-
pied by enzyme substrates or its inhibitors. Based on the appearance
of yellow color, as a result of peptide bond hydrolysis within the
H-D-Phe-Pip-Arg-pNA substrate and generation of p-nitroaniline, it
can be concluded that the thrombin catalytic center is available. The
thrombin ability to hydrolyze short peptide substrate in the presence
of tested TBA variants was determined by calculation of the percentage
of its activity maintenance (At). The absorbance for the thrombin
solution at 405 nm was assumed as 100% of At parameter value.
The highest level of thrombin activity was observed for TBA variants
containing UNA-C, UNA-G, UNA-s4U at position T7, UNA-C at
position T9, UNA-A at position T12, and unmodiﬁed TBA (Supple-
mental Information; Figure S1). The At value was above 100% for
all mentioned TBA variants. A slight decrease in thrombin At levels
(At < 100%) was observed when solutions contained TBA variants
modiﬁed with UNA-A at positions T3 or T7 and UNA-s4U at
positions T3 or T12. Statistical analysis by the p-Student’s test was per-
formed and the p-parameter for all observed differences in thrombin
At level in the presence of analyzed TBA variants determined (data
not shown). In all of the above cases, the p-parameter value was
greater than 0.05, and it was therefore concluded that the resulting
variation in thrombin activity levels in the presence of the studied
TBA variants was not statistically signiﬁcant. Hence it can be stated
that neither of the analyzed aptamers affect the ability of thrombin
to hydrolyze peptide substrate H-D-Phe-Pip-Arg-pNA, and that the
tested TBA variants exert their inhibitory effect by binding to exosite
I of thrombin molecule.
Surface Plasmon Resonance
In this paper, the dissociation constant (KD value) of thrombin-TBA
complex was determined using real-time surface plasmon resonance
spectroscopy. Surface plasmon resonance is an optical technique
that allows to determine the strength of interactions between two
molecules: one suspended in solution and the other immobilized on
a metallic surface, all based on the registration of the change in refrac-
tive index.46
It was previously reported that a favorable KD value is predominantly
obtained when introduction of modiﬁed nucleotides has no inﬂuence
on G-quadruplex structure and is localized in one of three TBA
loops.12 Herein, surface plasmon resonance measurements were
conducted for the group of TBA variants characterized by the most
beneﬁcial thermodynamic parameters and anticoagulant properties.
The most favorable KD values were obtained for TBA variants modi-
ﬁed with canonical UNAs and UNA-s4U residues at position T7 (the
KD values were 4.25, 4.39, 4.75, and 5.00 nM for UNA-G, UNA-C,
UNA-A, and UNA-s4U, respectively; Table 4). The surface plasmon
resonance data remain in a close correlation with thrombin time
assay results, what evidences for pronounced tolerance of position
T7 toward substitution with UNA residues. The similar observation
was made earlier upon analysis of the inﬂuence of single introduction
of UNA-U or UNA-G into TBA.22 Higher KD values were measured
for TBA variants containing canonical UNAs and UNA-s4U residues
at positions T3 or T9 (the KD values were 5.99, 6.67, and 8.77 nM for
UNA-A at T3, UNA-s4U at T3, and UNA-C at T9, respectively;
Table 4). The decrease in the strength of thrombin-TBA interactions
was also observed when UNA-A and UNA-s4U residues were intro-
duced into position T12 (the KD values were 10.91 and 15.99 nM for
UNA-A and UNA-s4U, respectively; Table 4).
In general, all TBA variants containing UNA-s4U residues were char-
acterized by higher KD values in comparison with variants modiﬁed
with canonical UNA residues. The results were partially reﬂected in
the AE values measured at 0.165 mM concentration (the higher AE,
the lower KD). A noticeable disagreement was observed for two
TBA variants containing UNA-G or UNA-s4U residues at positions
T7 and T12, respectively. In both cases, the KD values could not be
directly translated into the thrombin test results. This reﬂects the
complexity of blood coagulation processes and indicates that the
knowledge of the KD value alone is not sufﬁcient for the estimation
of the anticoagulant properties of TBA variants.
Antiproliferative Assay
In recent years there has been growing interest in the antiproliferative
potential of guanosine-rich oligonucleotides. These molecules usually
fold into G-quadruplex structures and are capable of binding to
speciﬁc proteins involved in the cell cycle that may result in cell
growth inhibition.47,48 The L. Mayol research group31 has shown
that the introduction of dibenzyl linker at speciﬁc TBA positions
causes a decrease in the anticoagulant properties of this aptamer while
increasing its antiproliferative potential.
Based on these reports, experiments on the inhibition of cervical
cancer cell growth (HeLa) by selected TBA variants using the MTT
test were performed. This method allows for evaluation of cell viability
based on the reduction of the water-soluble, yellow tetrazole salt
(MTT) into the insoluble dark blue formazan. The amount of reduced
Table 4. KD and Biostability (T1/2) of TBA and TBA Variants Modified with
Canonical UNAs (AU, CU, GU) and UNA-s4U (s4UU)
Position of Modiﬁcation Sequence (5ʹ-3ʹ) KD (nM) T1/2 (s)
GGTTGGTGTGGTTGG 4.23 59.3
T3 GGAUTGGTGTGGTTGG 5.99 ND
T7 GGTTGGAUGTGGTTGG 4.75 78.9
T7 GGTTGGCUGTGGTTGG 4.39 89.2
T7 GGTTGGGUGTGGTTGG 4.25 89.2
T9 GGTTGGTGCUGGTTGG 8.77 ND
T12 GGTTGGTGTGGAUTGG 10.91 ND
T3 GGs4UUTGGTGTGGTTGG 6.67 ND
T7 GGTTGGs4UUGTGGTTGG 5.00 66.9
T12 GGTTGGTGTGGs4UUTGG 15.99 ND
ND, not determined.
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MTT is directly proportional to the number of living cells on the
experimental plates. The initial selection of candidates from the total
pool of TBA variants was conducted via MTT screening test carried
out for the aptamers at two concentrations (0.1 and 5.0 mM; Supple-
mental Information; Table S4). The results of these experiments
indicated that introduction of canonical UNA residues into TBA at
positions T3, T4, T7, G8, T9, T12, or T13 caused only a slight decrease
in HeLa cell proliferation (the mean cell viability was 89.5% for
UNA-A, 86.5% for UNA-C, and 85.8% for UNA-G in 5.0 mM).
TBA variants modiﬁed with UNA-s4U possessed more favorable
inhibitory properties with a reduction of HeLa cell viability to around
75% at the highest concentration tested. The most pronounced anti-
proliferative activity was observed for aptamers bearing multiple
RNA-s4U substitution at positions T3, T7, T9, and T12 (or T13). Inter-
estingly, these TBA variants containing four RNA-s4U residues were
able to reduce HeLa cell viability to values below 50%.
Based on the above data, the detailed analysis of antiproliferative
properties was performed using 0.1, 5.0, and 10.0 mM concentration
of unmodiﬁed TBA and the two potent TBA variants modiﬁed with
RNA-s4U residues at positions T3, T7, T9, and T12 (or T13).
The data analysis revealed that the HeLa cell viability was reduced by
11% in the presence of 0.1 mM TBA variant modiﬁed with RNA-s4U
residues at positions T3, T7, T9, and T12 (Figure 4; Supplemental
Information; Table S5). The effect was gradually enhanced with an
increase in oligomer concentration in the cell medium, reaching the
85% inhibition at 10 mM. A similar trend was observed for the ap-
tamer modiﬁed with RNA-s4U residues at positions T3, T7, T9, and
T13. Notably, the inhibitory effect for the RNA-s4Umodiﬁed aptamer
at 10 mM concentration was 95%. Interestingly, the unmodiﬁed TBA
in 5 mM concentration was 3-fold less potent than the two analyzed
TBA variants, and at 10.0 mM concentration TBA caused a reduction
in HeLa cell viability by only 66%. These results highlight that switch-
ing the TBA activity from anticoagulant to antiproliferative is possible
not only by replacement of a single loop nucleoside with a dibenzyl
linker,31 but also via nucleobase and sugar moiety modiﬁcation.
Viability in Human Serum
The rapid elimination of aptamers from the bloodstream and their
susceptibility on nucleases digestion are major factors limiting the
biological effects of oligonucleotides in the human body.49 The
biostability of oligonucleotides in human serum can be assessed by
designation of their half-life (T1/2), deﬁned as the time needed to
reduce the amount of tested substance by half. It is known that the
introduction ofmodiﬁed nucleotide residues into an aptamer can result
in a favorable T1/2 value as shown for UNA-containing G-quadruplex
structures.50
Herein, the T1/2 value for selected TBA variants characterized by the
most beneﬁcial anticoagulant or antiproliferative properties was
determined via incubation in human serum at 37C. The TBA vari-
ants modiﬁed with UNA-C or UNA-G at position T7 displayed the
most favorable value of serum stability. In both cases, T1/2 was
equal to 89.2 min in comparison with 59.3 min for unmodiﬁed
TBA (Table 4). The T7 substitution by UNA-A also increased resis-
tance of the aptamer to degradation; however, in this case, the T1/2
was equal to 78.9 min (Table 4). Only slight extension of biostability
was observed for TBA variants containing UNA-s4U at position T7
(T1/2 was 66.9 min; Table 4). The achieved results are consistent
with previous literature data, thus conﬁrming that the introduction
of UNA modiﬁcations can have a beneﬁcial inﬂuence on in vitro
stability of DNA G-quadruplex in serum.50
Interestingly, the determination of biostability of the two TBA vari-
ants modiﬁed with four RNA-s4U residues at positions T3, T7, T9,
and T12 (or T13) was impossible due to the presence of additional
products characterized by retarded electrophoretic mobility (Supple-
mental Information; Figure S2). Previously, it was described that the
introduction of sulfur modiﬁcation of nucleotide residues or the
phosphodiester linkage of an oligonucleotide chain can result in
increased afﬁnity to proteins.20,51,52 Taking under consideration the
above literature reports, the additional bands could originate from
the formation of complexes between the TBA variants and serum
proteins.
Conclusions
In this paper, a novel UNA derivative, i.e., UNA-4-thiouracil, has
been synthesized and introduced into oligonucleotides for the ﬁrst
time. Furthermore, detailed analysis of the inﬂuence of single and
multiple introduction of 4-thiouridine or UNA-4-thiouracil, as well
as regular UNA-A, UNA-C, UNA-G, and UNA-U into TBA, on ther-
modynamic and biological properties was performed.
The most favorable thermodynamic parameters were achieved by the
introduction of RNA-s4U or UNA-s4U at positions T3, T7, or T12 and
UNA-A, UNA-C, and UNA-G residues at position T7 of the TBA
aptamer. In addition, RNA-s4U substitution resulted in stronger
Figure 4. The Antiproliferative Activity of Unmodified TBA (Black Bars) and
TBA Variants Modified with RNA-s4U at T3, T7, T9, and T13 (Red Bars) or at
T3, T7, T9, and T12 (Red Crosshatch Bars)
All data are presented as the mean ± SEM from three independent experiments
(*p < 0.05, Student’s t test; n = 3).
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stabilization of G-quadruplex structure in comparison with UNA-
s4U substitution. Interestingly, the thermodynamic effects obtained
by simultaneous introduction of the nucleobase-modiﬁed UNA or
RNA nucleotides were additive. The structural studies conﬁrmed
that the TBA variants had preserved folding topology and retained
the intramolecular, antiparallel G-quadruplex structure of TBA at
37C. Thrombin time assay revealed that the oligonucleotides
possess concentration-dependent anticoagulant properties. Notably,
at higher concentration two variants modiﬁed with UNA-A or
UNA-C at position T7 displayed more efﬁciently thrombin inhibition
than unmodiﬁed TBA. The most favorable KD value and extended
biostability in human serum were achieved for TBA variants possess-
ing UNA-s4U or canonical UNA nucleotides at position T7. Taken
together, these results suggest that T7 nucleotide substitution allows
for maintenance of favorable thermodynamic stability and biological
activity. Furthermore, the introduction of canonical UNA nucleotides
or UNA-s4U into position T7 of TBA was beneﬁcial not only for its
thermodynamic parameters and anticoagulant properties, but also
for improved TBA biostability in human serum. In general, it can
be concluded that G-quadruplex structure is crucial for TBA antico-
agulant properties. Nevertheless, the improvement of thermody-
namic stability does not guarantee the increase in TBA inhibitory
activity against thrombin. Interestingly, some TBA variants with
poor anticoagulant properties were shown to be efﬁcient antiprolifer-
ative agents. Herein, we demonstrate that two compounds containing
multiple substitution of RNA-s4U at positions T3, T7, T9, and T12
(or T13) exhibited a potential to inhibit HeLa cell growth. In the
future, our ﬁndings have the potential to serve as the basis for design
and selection of compounds with the necessary improved biological
properties for therapeutic applications.
MATERIALS AND METHODS
Chemical Synthesis of 20-O-Benzoyl-30-O-(2-
cyanoethoxy(diisopropylamino)phosphino)-50-O-
(4,40-dimethoxytrityl)-20,30-seco-4-thiouridine
The synthesis of UNA-4-thiouridine derivative was performed
according to the general published procedure for synthesis of
UNA phosphoramidites53 with some modiﬁcations. Uridine was
treated with TBDMSCl followed by NaIO4 and NaBH4. O50-TBDMS-
protected 20,30-secouridine was acetylated and then converted into
4-thiouridine derivative using Lawesson reagent. This acyclic derivative
of 4-thiouridine was afterward treated with Et3N$3HF followed
by DMTCl and Et3N/MeOH to give O50-DMT-protected UNA-4-
thiouracil. Selective benzoylation of O20 was performed according
to the previously published protocol.53 Treatment of the resulting
compound with 2-cyanoethyl-N,N,N0,N0-tetraisopropylphosphor-
diamidite gave the ﬁnal UNA-4-thiouracil building block suitable
for oligonucleotide synthesis in an overall yield ca. 25%. Synthetic
details are described in the Supplemental Information.
Chemical Synthesis of Oligonucleotides
All oligonucleotides were synthesized on an automated RNA/DNA
synthesizer using standard phosphoramidite chemistry.54 The details
of deprotection and puriﬁcation procedures used for unmodiﬁed
oligoribonucleotides or TBA variants containing nucleotide residues
in the UNA series were described previously.53,55 Deprotection of
TBA variants modiﬁed with RNA-s4U or UNA-s4U was performed
by treatment with methanol/aqueous ammonia solution (1:1 v/v) at
room temperature for 48 hr. Puriﬁcation was accomplished according
to general procedures.56 The composition of all oligonucleotides was
conﬁrmed by MALDI-TOF mass spectrometry.
UV Melting Analysis
Oligonucleotides were dissolved in a buffer containing 100 mM
potassium chloride, 20 mM sodium cacodylate, and 0.5 mM
Na2EDTA (pH 7.0). Single-stranded oligonucleotide concentrations
were calculated based on the absorbance measured above 80C,57
and the extinction coefﬁcients were calculated using Oligo Calcu-
lator (http://www.ribotask.com). The samples were denatured at
95C for 5 min and then cooled to room temperature overnight.
The measurements were performed for nine different concentra-
tions of the G-quadruplexes in the concentration range of 104 to
106 M. Absorbance versus temperature curves were obtained using
the UV melting method at 295 nm in the temperature range of 4C
to 90C with a heating rate of 0.2C/min on a JASCO V-650 spectro-
photometer equipped with a thermoprogrammer. Melting curves
(Supplemental Information; Figure S3) were analyzed and the
thermodynamic parameters determined by nonlinear curve ﬁtting
using the MeltWin 3.5 software. Melting temperatures calculated
for a 104 M concentration of oligonucleotide are denoted by TM,
and melting points for any other concentration of oligonucleotide
are denoted by Tm.
Circular Dichroism Spectra
CD spectra were recorded on a JASCO J-815 spectropolarimeter. The
oligonucleotides were dissolved in a buffer containing 100 mM potas-
sium chloride, 20 mM sodium cacodylate, and 0.5 mM Na2EDTA
(pH 7.0) to achieve a sample concentration of 3.0 mM. All samples
were denatured at 95C for 5 min and then slowly cooled to room
temperature overnight prior to data collection. The spectra were
recorded in triplicate at 37C in the 205 to 320 nm wavelength range.
The buffer spectrum was subtracted from the sample spectra. The
data analysis was performed using the Origin 8.0 software.
Thermal Difference Spectra
The TDS measurements were performed on a JASCO V-650
spectrophotometer equipped with a thermoprogrammer. The oligo-
nucleotides were dissolved in a buffer containing 100 mM potas-
sium chloride, 20 mM sodium cacodylate, and 0.5 mM Na2EDTA
(pH 7.0), to achieve a sample concentration of 0.1 mM. Absorbance
spectra were recorded in triplicate at 4C and 90C in the 220 to
335 nm wavelength range. The scan speed was 1,000 nm/min
with a 1-nm data interval. Thermal difference spectra were obtained
by subtraction of the low-temperature absorbance spectra from the
high-temperature absorbance spectra using the Origin 8.0 software.
The differential spectra were normalized by dividing the data by its
maximum value.35
www.moleculartherapy.org
Molecular Therapy: Nucleic Acids Vol. 10 March 2018 313
Thrombin Time Assay
The thrombin time assay was performed using commercially avail-
able Dia-TT kit (DIAGON) and coagulometer K-3002 Optic. Each
reaction mixture consisted of TBA variant (0.33 mM) dissolved in
100 mL of Dia-TT reagent. The reaction mixture was incubated at
37C for 5 min and put into a sample well of coagulometer K-3002
Optic. Next, 100 mL of citrate plasma was added. Each TBA variant
was analyzed using plasma samples derived from ﬁve healthy volun-
teers. The sample from each volunteer was measured twice, and the
thrombin time values obtained from the double measurements did
not exceed 6% (Supplemental Information; Table S6). The anticoag-
ulant effect was obtained by subtraction of the time needed for plasma
clotting in the presence of the aptamers from the time needed for
clotting of plasma without aptamer. In addition, thrombin time for
TBA variants with the best anticoagulant properties in seven different
concentrations, 0.0825, 0.165, 0.330, 0.495, 0.660, 0.825, and 1 mM,
was assigned using plasma samples derived from three healthy
volunteers (Supplemental Information; Table S2). Each experiment
was repeated twice and the result expressed as mean value.
Surface Plasmon Resonance
The value of KD for chosen TBA variants was measured using a
BIAcore X100 system (GE Healthcare Life Science), human alpha-
thrombin solution (Haematologic Technologies), commercially avail-
able Biotin CAPture KIT, and Sensor Chip SA (GE Healthcare Life
Science). The 50-biotinylated oligonucleotides were dissolved in a
running buffer, 10 mM PBS (138 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.76 mM KH2PO4, 0.05% Tween 20 [pH 7.4]), to achieve
a sample concentration of 1 mM. The samples were denatured at 95C
for 6 min and then cooled to room temperature overnight. The
oligonucleotides were immobilized on a chip surface via the strepta-
vidin-biotin coupling method. The ﬂow rate was set to 30 mL/min,
and the unbound oligonucleotide was removed by the treatment
with 50 mM aqueous NaOH. Next, serially diluted thrombin solution
in the concentration range of 12.5 to 200 nM along with a BSA
(Sigma-Aldrich) and sample with only running buffer were injected.
The measurements were performed at 25C. After each run, the sys-
tem was regenerated by treatment with 50 mM aqueous NaOH. Data
analysis was performed using the BIAcore X100 Evaluation software
and a 1:1 binding mode.
Amidolytic Assay
Amidolytic assay was used to evaluate the ability of human alpha-
thrombin (Haematologic Technologies) to hydrolyze chromogenic
substrate H-D-phenylalanyl-L-arginine-p-nitroaniline (H-D-Phe-Pip-
Arg-pNA, trade name: S-2238; CHROMOGENIX) in the presence of
chosen TBA variants. The reaction mixture (150 mL), consisting of
the chosen TBA variants (1 mM), thrombin (0.4 U/mL) and reaction
buffer (0.1 M Tris [pH 8.2], 150 NaCl, 5 mM KCl, 0.1% BSA), was
incubated at 37C for 5 min. Next, 50 mL of 2 mM chromogenic
substrate H-D-Phe-Pip-Arg-pNA was added. The amount of released
p-nitroaniline was measured at 405 nm using a microplate reader
xMark (Bio-Rad). Data analysis was performed using Microsoft Excel
2013 software. Each experimentwas repeated in triplicate and the result
expressed as mean value.
Viability of Oligonucleotides in Human Serum
The amount of 1  106 cpm of 32P-labeled oligonucleotides was
dissolved in 1 PBS buffer containing 100 mM potassium chloride.
The samples were denatured at 90C for 6 min and then cooled to
room temperature overnight. After this time, 200 mL of human serum
from human male AB plasma (Sigma-Aldrich) was added, and the
samples were incubated at 37C. Aliquots of 5 mL were removed after
0, 10, 20, 40, 60, 120, 180, and 1,440 min of incubation and were then
mixed with 5 mL of a 70% deionized formamide solution containing
50 mM EDTA and cooled on dry ice to quench the reaction.
The samples were loaded on a 12% denaturing polyacrylamide gel pre-
pared in 1 TBE buffer. PAGE in denaturing condition was performed
in 1 TBE buffer at 20 W for 3 hr at room temperature. The resultant
gel was imaged and quantiﬁed by storage phosphor technology using a
Fuji PhosphorImager and MultiGauge Analysis Software.
Antiproliferative Assay
The antiproliferative properties of TBA variants were evaluated via
MTT assay. The oligonucleotide solutions in concentrations of 1,
50, and 100 mM were prepared in 1 PBS buffer with 100 mM
KCl. The samples were denatured at 95C for 6 min and then cooled
to room temperature overnight. The experiments were conducted on
cervical carcinoma cells (HeLa cell line), which were seeded in a 96-
well plates at a density of 250 cells/well in 100 mL of RPMI 1640 me-
dium (Sigma-Aldrich) supplemented with 10% fetal bovine serum
(Sigma-Aldrich) and 1 vitamin solution (Sigma-Aldrich). The
plates were cultured at 37C, 5% CO2, and a relative humidity of
100% for 24 hr. Next, the HeLa cells were exposed to varying concen-
trations of the chosen TBA variants (0.1, 5.0, 10.0 mM, ﬁnal working
volume: 200 mL) for 7 days. All appropriate control reactions were
conducted. Afterward, the growth medium was removed and 1
MTT solution (Sigma-Aldrich) in RPMI 1640 media was added.
The cells were incubated at 37C in an atmosphere of 5% CO2 and
a relative humidity of 100% for 2 hr. Next, the medium was removed
and replaced with an aqueous mixture of 70% isopropanol and
40mMHCl (100 mL/well) in order to dissolve the blue-purple crystals
of formazan. The plates were shaken at 80 rpm for 30 min at room
temperature. The amount of released formazan was measured at
595 nm using a microplate reader xMark (Bio-Rad). Data analysis
was performed usingMicrosoft Excel 2013 software. Each experiment
was repeated in triplicate and the result expressed as mean ± SD.
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